# Precision Immuno-Oncology for Advanced Non-small Cell Lung Cancer Patients With PD-1 ICI Resistance

> **NCT03833440** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Assistance Publique Hopitaux De Marseille** · enrollment: 114 (actual)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Durvalumab (MEDI4736)
- **DRUG:** Monalizumab (IPH2201)
- **DRUG:** Oleclumab (MEDI9447)
- **DRUG:** Ceralasertib (AZD6738)
- **DRUG:** DOCETAXEL
- **DRUG:** Savolitinib

## Key facts

- **NCT ID:** NCT03833440
- **Lead sponsor:** Assistance Publique Hopitaux De Marseille
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-10-08
- **Primary completion:** 2024-10
- **Final completion:** 2025-02
- **Target enrollment:** 114 (ACTUAL)
- **Last updated:** 2024-05-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03833440

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03833440, "Precision Immuno-Oncology for Advanced Non-small Cell Lung Cancer Patients With PD-1 ICI Resistance". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT03833440. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*